Full Press Release Details
MINUTES of the proceedings at the
annual general meeting of Mainz Biomed N.V., a public company under Dutch law, registered with the Dutch trade register under
number 82122571 (the "Company"), held at the offices of CMS Netherlands, Atrium, Parnassusweg 737, 1077 DG
Amsterdam, the Netherlands, on 28 June 2022 at 15.00 hours CET,
Chairman and secretary
Hans Hekland (Chairman of the Board of the Company,
present in person) acts as chairman of the meeting and Martijn van der Bie (civil law notary with CMS, present in person) as secretary.
The chairman opens the meeting. It is noted that
the meeting takes place in accordance with the articles of association of the Company and Dutch law. The convocation, agenda and other
meeting documents were available on the Company website as of 20 May 2022 and filed with the US Securities and Exchange Commission on
SEC Form 6-K on 3 June 2022.
It is noted that a total of 13,735,000 ordinary
shares in the capital of the Company are issued and outstanding. The holders of not less than 2,971,015 ordinary shares are present by
proxy. 21.63% of the voting power on the outstanding shares is present or represented at the meeting. Each share confers the right to
It is noted that no persons with meeting rights
have submitted resolutions for adoption at the general meeting.
The chairman considers the agenda of the meeting,
which includes the consideration of the annual accounts over the financial year ended on 31 December 2021.
Since the attendees indicated they had no questions
or comments in respect of the items included on the agenda for the meeting, the chairman proceeds and puts each of the voting items on
the agenda to the vote. The chairman notes that each voting item is adopted with the requisite majority.
There being no further questions or comments from
the attendees, the chairman closes the meeting.